CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:In vitro evaluation of antiviral activity of Sisybrium irio (Khaksi) against SARS-COV-2.
In vitro evaluation of antiviral activity of Sisybrium irio (Khaksi) against SARS-COV-2.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
SARS-CoV-2 大流行引起了对病毒培养需求的关注。进行体外 SARS-COV-2 培养以开展治疗、环境和病毒基因组研究。通过将病毒阳性样本接种到可用细胞系中,从鼻咽拭子中分离病毒。使用扫描电子显微镜 (SEM) 观察 SARS-CoV-2 的形态。病毒特异性通过使用 COVID 19 恢复期血清进行中和试验的血清学确认来定义。SARS-COV-2 病毒在 Vero 细胞系(E6 和 CCL-81 中均)成功复制。分离病毒的 TCID50 和 PFUs 分别定义为 10 7 TCID 50 /mL 和 1.4 Х 10 6 pfu/mL。具有 SARS-COV 形态的病毒颗粒大小 <150ɳM。观察到在 COVID-19 患者恢复期血清存在下病毒受到抑制。发现 Sisybrium irio (Khaksi) 对 Vero E6 细胞系具有细胞毒性,并且其抗病毒活性无法在体外针对 SARS-COV-2 病毒得到证实。成功分离并保存的本地 SARS-COV-2 可进一步用于治疗、环境和病毒基因组测序研究。
SARS-CoV-2 pandemic, drawn attention to the need of virus culture. In vitro SARS-COV-2 culture was performed to carry out therapeutic, environmental and virus genome studies. Isolation of virus from nasopharyngeal swab was performed by inoculating virus positive samples in available cell lines. SARS-CoV-2 topography was observed by using Scanning Electron Microscopy (SEM). Virus specificity was defined by serological confirmation through neutralization assay with COVID 19 convalescent sera. The SARS-COV-2 virus replicated successfully in Vero cell lines (both in E6 and CCL-81).
The TCID50 and PFUs of isolated virus were defined as 10 7 TCID 50 /mL and 1. 4 Х 10 6 pfu/mL respectively. The virus particles with the SARS-CoV morphology was <150ɳM size. Virus inhibition in presence of convalescent sera of COVID-19 patients was observed. Sisybrium irio (Khaksi) was found cytotoxic on Vero E6 cell line and its antiviral activity could not be established against SARS-COV-2 virus in vitro. Successful isolated and archived native SARS-COV-2 may be utilized further for therapeutic, environmental and virus genome sequencing studies.
MEMBER ACCOUNT
登录成功会直接打开下一页。